Molecular Processes Involved in the Shared Pathways between Cardiovascular Diseases and Diabetes

Area of Science:

• Endocrinology
• Cardiology
• Microbiology

Background:

• Cardiovascular diseases (CVD) and diabetes mellitus are leading causes of morbidity and mortality worldwide.
• Inflammation is a key factor in the pathogenesis and development of both conditions.
• Gut microbiota dysbiosis may influence the progression of diabetes and CVD.

Purpose of the Study:

• To review the latest knowledge and innovations in managing diabetes mellitus and CVD.
• To focus on the molecular mechanisms linking these diseases.
• To explore the role of gut microbiota in their pathogenesis and treatment.

Main Methods:

• Literature review of recent studies on diabetes mellitus and cardiovascular diseases.
• Analysis of molecular mechanisms involved in disease development.
• Investigation of the impact of gut microbiota composition.

Main Results:

• SGLT-2 inhibitors and GLP-1 receptor agonists demonstrate a dual therapeutic effect on both diabetes and CVD.
• Inflammation is a central pathway connecting the pathogenesis of these diseases.
• Alterations in gut microbiota composition are associated with increased risk and progression of diabetes and CVD.

Conclusions:

• Targeting inflammation and modulating gut microbiota represent promising therapeutic strategies for patients with diabetes and CVD.
• SGLT-2 inhibitors and GLP-1 receptor agonists offer a dual benefit, addressing both conditions effectively.
• Further research into the interplay between gut microbiota, inflammation, and metabolic/cardiovascular health is warranted.